Get the Stockscreener App
214.35
1.11%
-2.40
After Hours:
214.45
0.10
+0.05%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $214.35, with a volume of 8.59M.
It is down -1.11% in the last 24 hours and down -4.17% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$216.75
Open:
$215.61
24h Volume:
8.59M
Relative Volume:
1.49
Market Cap:
$378.84B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
161.74
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-2.60%
1M Performance:
-4.17%
6M Performance:
+12.47%
1Y Performance:
+23.40%
1-Day Range:
$213.88
$217.34
1-Week Range:
$213.88
$223.34
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
214.35 | 383.08B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,038.40 | 924.53B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.66 | 529.01B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVO
Novo Nordisk Adr
|
62.33 | 253.81B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
NVS
Novartis Ag Adr
|
144.34 | 274.68B | 54.45B | 14.42B | 17.15B | 7.333 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Could Buying This Stock Today Pay Off Big Over the Next 5 Years? - Finviz
Could Buying This Stock Today Pay Off Big Over the Next 5 Years? - The Motley Fool
Key facts: AbbVie to invest $100B in U.S. research; Phase 3 trial shows progress - TradingView — Track All Markets
AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next - TechStock²
PRESCRIPTION DRUGS—N.D. Ill.: Complaint that AbbVie violated state consumer protection statutes dismissed - VitalLaw.com
AbbVie Call Options Spike 2,599%: Tracking the Big Bet - Finviz
AbbVie and Genmab Advance Epcoritamab with Significant PFS Improvement in DLBCL Trial - Intellectia AI
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst - TechStock²
AbbVie Announces Topline Results for Epcoritamab from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Investing News Network
AbbVie (ABBV) Phase 3 Trial Shows Progression-Free Survival Impr - GuruFocus
Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study - TradingView — Track All Markets
Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma - Seeking Alpha
AbbVie (ABBV) and Genmab Advance Epcoritamab Trials for Lymphoma - GuruFocus
AbbVie reports mixed results in phase 3 lymphoma trial By Investing.com - Investing.com Canada
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Yahoo Finance
AbbVie Expands Oncology Pipeline With First-in-Human ABBV-711 Trial in Advanced Squamous Tumors - TipRanks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Glaukos (GKOS) - The Globe and Mail
Zacks Research Comments on AbbVie's Q1 Earnings (NYSE:ABBV) - MarketBeat
JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency - Pharmaceutical Technology
Rx Rundown: Nvidia, Johnson & Johnson, AbbVie and more - Medical Marketing and Media
AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains - Yahoo Finance
Investors Purchase Large Volume of AbbVie Call Options (NYSE:ABBV) - MarketBeat
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts - Yahoo Finance
AbbVie (NYSE:ABBV) Shares Down 2.4%Time to Sell? - MarketBeat
Atopic Dermatitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan - Barchart.com
AbbVie stock slides 2% as obesity push takes center stage at JPM conference - TechStock²
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
J.P. Morgan: AbbVie Still Aims To Be A Major Obesity Player – With A Lift From Botox - Citeline News & Insights
AbbVie Advances Obesity Pipeline With Completion of First-in-Human GUB014295 Trial - TipRanks
The Zacks Analyst Blog Highlights AbbVie, Intel, Boeing and Tandy Leather Factory - Yahoo Finance
BMO Capital reiterates Outperform rating on AbbVie stock amid growth By Investing.com - Investing.com UK
AbbVie Inc. $ABBV Shares Bought by Meritage Portfolio Management - MarketBeat
Why AbbVie Has Committed $100bn to US Medicine Supply Chains - Procurement Magazine
How AbbVie’s $100bn Investment Reshapes Pharma Supply Chains - Supply Chain Digital Magazine
AbbVie’s US$100bn Deal Could Transform US Healthcare Access - Healthcare Digital
Conning Inc. Decreases Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly - Stocktwits
AbbVie: stepping up obesity treatments with an alternative approach to GLP-1 - marketscreener.com
Rep. Julia Letlow Sells Off Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie stock in focus after hours as it eyes obesity market — what to watch next - TechStock²
Top Research Reports for AbbVie, Intel & Boeing - Yahoo Finance
AbbVie plans to build out its presence in obesity market - Reuters
AbbVie Reaches Agreement With Trump Administration, Joining MFN Initiatives - Pharmacy Times
AbbVie to invest $100 billion in the U.S in exchange for tariff exemptions - The American Bazaar
JP Morgan 2026: AbbVie Advances its Pipeline - PharmExec.com
Key facts: AbbVie Reports Growth in Immunology, Neuroscience; Targets Weight-Loss Market - TradingView — Track All Markets
AbbVie sets sights on immunology, neurology dominance - Crain's Chicago Business
AbbVie Bets Big on Chinese Cancer Drug in $5.6 Billion Licensing Deal - Caixin Global
AbbVie Joins TrumpRx in Exchange for Tariff Relief and Pricing Flexibility - Pharmaceutical Commerce
AbbVie (ABBV) Rises on Agreement for Drug Pricing and Investment Commitment - GuruFocus
Ex-Dividend Reminder: AbbVie, Dime Community Bancshares and MidWestOne Financial Group - Nasdaq
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.12%
1.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):